AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT01478503 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: mirabegron OCAS
Description: oral
Study NCT01478503 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: oral
Study NCT03742518 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Topical vehicle solution
Description: Vehicle solution application will be performed by the individual subject at approximately the same time each day.
Study NCT00439764 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: General health talk
Description: Routine clinical practice and talk on general health
Study NCT00439764 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Handout of The Back Book
Description: Talk on health of the back and handout of The Back Book
Study NCT00439764 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Back exercise
Description: Routine clinical practice, talk on back health, handout of The Back Book and back exercise
Study NCT02223962 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Physical activity
Description: Counseling about physical activity will only be provided in the intervention group by 3 weekly telephone contacts. Based on the information the physiotherapist receives, he or she will adapt the goal (in agreement with the patient) and motivate the patient to reach the individual goal.
Study NCT02223962 — intervention group
Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: Physical activity
Description: Counseling about physical activity will only be provided in the intervention group by 3 weekly telephone contacts. Based on the information the physiotherapist receives, he or she will adapt the goal (in agreement with the patient) and motivate the patient to reach the individual goal.
Study NCT00053196 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: anti-thymocyte globulin
Description: 2.5mg/kg/day IV infusion over 6 hrs x 4 doses Days -4 to -1 (for MUD and 9/10 related donor transplants only)
Study NCT00053196 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: G-CSF
Description: 5 ug/kg/day subQ injection Day 7 until ANC> 1000/uL for 3 consec days
Study NCT00053196 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: busulfan
Description: 0.8mg/kg IV infusion over 2 hrs q 6 hrs x 8 doses Days -4 thru -3
Study NCT00053196 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: fludarabine phosphate
Description: 30 mg/sq m/day IVBP over 30 min Days -7 thru -3
Study NCT04390139 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: XCEL-UMC-BETA
Description: Administration on top of the standard administered treatment
Study NCT00053196 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: methotrexate
Description: 5 mg/sq m/day IV infusion Days 1, 3, \& 6 for HLA-identical donor transplants and Days 1, 3, 6, \& 11 for MUD \& 9/10 related donor transplants
Study NCT00053196 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: mycophenolate mofetil
Description: 15mg/kg PO bid Day -2 to Day 60, then taper as tolerated (for MUD and 9/10 related donor transplants only)
Study NCT00053196 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: tacrolimus
Description: target serum level is 5-10 ng/mL. Start with 0.03mg/kg PO bid Day -1 to Day 90, then taper thru Day 150 for HLA identical donor transplants and Day -1 to Day 180 then taper for MUD and 9/10 related donor transplants
Study NCT00053196 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: allogeneic cell transplantation
Description: 2,000,000-8,000,000 CD34+ cells total via infusion Days 0 and 1
Study NCT00053196 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: allopurinol
Description: 300 mg/day PO Days -8 thru -1
Study NCT04009525 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Busulfan
Description: Busulfan（4 mg/kg/day,4 days）
Study NCT04009525 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cyclophosphamide
Description: Cyclophosphamide（50 mg/kg/day,4 days）
Study NCT04009525 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fludarabine
Description: Fludarabine（50 mg/m2/day,3 days）
Study NCT04009525 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Thymoglobulin
Description: Thymoglobulin（2.5 mg/kg/day,4 days）
Study NCT04009525 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: cyclosporine A
Description: cyclosporine A
Study NCT04009525 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Mycophenolate mofetil
Description: Mycophenolate mofetil（0.25g/day）
Study NCT04009525 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tacrolimus
Description: Tacrolimus
Study NCT04009525 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Methotrexate
Description: Methotrexate
Study NCT00595920 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Tovaxin
Description: 2 mL subcutaneous injections administered by a healthcare provider at weeks 0, 4, 8, 12, and 24 every year as required.
Study NCT01877642 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Lorazepam 1 mg IM
Description: Lorazepam 1 mg intramuscular
Study NCT04390139 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Administration on top of the standard administered treatment
Study NCT01877642 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Inhaled loxapine 10 mg
Description: Inhaled Staccato loxapine 10 mg
Study NCT04434859 — intervention group
Intervention type: OTHER
Intervention: No intervention
Description: No intervention
Study NCT00989079 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ertugliflozin
Description: Ertugliflozin will be administered as an extemporaneously prepared suspension/solution for all doses within the initially planned range.
Study NCT01877642 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Inhaled Placebo
Description: Inhaler with no drug in it to mimic the ADASUVE inhaler
Study NCT01877642 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Placebo IM
Description: intramuscular placebo to mimic lorazepam 1 mg IM
Study NCT01818271 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: conventional physical therapy
Description: will receive a conventional out-patient program which will include: lower extremity stretching and strengthening exercise; fitness using cycle ergometer; balance exercises in standing; over ground walking and stair exercises
Study NCT01818271 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: community-based group rehabilitation
Description: Group training will include different workstations to target dynamic standing balance and walking. The key features includes facilitate repetition of task-related movements, tailored to the patient and patient's goals, in a meaningful context. Specifically:~* Advanced dynamic tasks, including stepping and other transitional tasks to treadmill \& over ground walking) with use of various inexpensive exercise assistive equipment such as mini-exercise stepper or elliptical machines.~* Treadmill walking exercise program.
Study NCT00989079 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo to Ertugliflozin
Description: Correspondingly placebo doses to ertugliflozin will be administered as suspension/solution
Study NCT03825796 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Enasidenib Mesylate
Description: Given PO
Study NCT00852085 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Enhanced community service
Description: Two educational sessions and volunteering at a local community service site
Study NCT00852085 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Group MI
Description: Four group counseling sessions and two directed observational visits to an emergency department
Study NCT04324879 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TQ-B3525
Description: TQ-B3525 tablet administered 20mg orally, once daily in 28-day cycle.
Study NCT02166242 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ethaselen
Description: ethaselen is a specific thioredoxin reductase inhibitor, which has finished phase 1a study in China, phase 1 study of ethaselen showed that 600 mg ethaselen bid could be well tolerated
Study NCT01162499 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Exendin-(9-39)
Description: IV infusion of exendin-(9-39) for 5 hours
Study NCT01162499 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Exendin-(9-39)
Description: IV infusion of exendin-(9-39) for 5 hours
Study NCT01162499 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Vehicle
Description: Normal saline (vehicle) infusion for 5 hours at 0.06 mL/kg/hr
Study NCT01162499 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Vehicle
Description: Normal saline (vehicle) infusion for 5 hours at 0.06 mL/kg/hr
Study NCT03825796 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Liposome-encapsulated Daunorubicin-Cytarabine
Description: Given IV
Study NCT00454363 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Laboratory Biomarker Analysis
Description: Correlative studies
Study NCT00454363 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pazopanib Hydrochloride
Description: Given PO
Study NCT00454363 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Pharmacological Study
Description: Correlative studies
Study NCT03906617 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Intercostal nerve block and wound infiltration with liposomal bupivacaine
Description: Intercostal nerve block and wound infiltration with liposomal bupivacaine during robotic lung resection surgery. 266mg of liposomal bupivacaine with 24 ml of 0.5% bupivacaine will be used.
Study NCT03906617 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Intercostal nerve block and wound infiltration with bupivacaine/epinephrine + dexamethasone
Description: Intercostal nerve block and wound infiltration with liposomal bupivacaine during robotic lung resection surgery. 42 ml of 0.5% Bupivacaine/epinephrine with 8mg dexamethasone will be used.
Study NCT01268982 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: socket preservation
Description: sockets will be filled with DFDBA and covered with absorbable membrane. Primary coverage will be achieved by full thickness mucosal flap advancement over each socket
Study NCT02237469 — intervention group
Intervention type: RADIATION
Intervention: Prone and supine simulation
Description: Treatment planning in the two positions.
Study NCT05428683 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: intra-vitreal triamcinolone-moxifloxacin injection after cataract surgery as a prophylactic measures against post-operative endophthalmitis
Description: At the end of surgery, 4mg triamcinolone acetonide and 0.2mg moxifloxacin from 0.5 moxifloxacin preservative-free eye drop) were injected once inferotemporally 3.5 mm posterior to the limbus via pars plana into the vitreous cavity by using 30 G needle.
Study NCT02588612 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: letetresgene autoleucel (GSK3377794)
Description: letetresgene autoleucel (GSK3377794) as an IV infusion.
Study NCT02588612 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cyclophosphamide
Description: Cyclophosphamide will be used as a lymphodepleting chemotherapy.
Study NCT02588612 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fludarabine
Description: Fludarabine will be used as a lymphodepleting chemotherapy.
Study NCT05215977 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MW031
Description: The active ingredient of MW031 is a recombinant human anti-RANKL monoclonal antibody ,subcutaneous injection of 60 mg (1.0 mL)every 6 months for a maximum of 2 consecutive doses throughout the trial.~Dietary Supplement: Elemental Calcium Oral, at least1000 mg Dietary Supplement: Vitamin D Oral, 400 IU
Study NCT05215977 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: subcutaneous injection of 60 mg (1.0 mL)every 6 months for a maximum of 2 consecutive doses throughout the trial.~Dietary Supplement: Elemental Calcium Oral, at least1000 mg Dietary Supplement: Vitamin D Oral, 400 IU
Study NCT01535417 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Shinbaro Capsule
Description: Herbal drug (Ledebouriellae Radix, Achyranthis Radix, Acanthopanacis Cortex, Cibotii Rhizoma, Glycine Semen, Eucommiae Cortex)
Study NCT01535417 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Celebrex
Study NCT03248999 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: rectal swab
Description: stool samples by rectal swab
Study NCT03955705 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nefopam 20 mg/ml
Description: Nefopam is a benzoxazocine derivative which is non-opioid and non NSAIDs. The previous studies showed that nefopam can inhibit reuptake of serotonin, norepinephrine and dopamine.
Study NCT03955705 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Normal saline
Description: 0.9% Sodium chloride (normal saline or NSS)
Study NCT00566241 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: recombinant human IGF-1
Description: rhIGF-1
Study NCT00566241 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo
Study NCT03641014 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: pH Effect on blastocyst formation
Description: to investigate which pH is suitable for each stage of embryo development
Study NCT00717912 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Experimental sweetener syrup
Description: 3 glucose and insulin responses with experimental sweetener syrup : 50 grams of digestible carbohydrate plus fiber
Study NCT00717912 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Classical sweetener syrup
Description: 1 glucose and insulin responses with classical sweetener syrup : 50 grams of digestible carbohydrate plus fiber
Study NCT00717912 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Classical sugar syrup
Description: 3 glucose and insulin responses with classical sugar syrup : 50 grams of digestible carbohydrate plus fiber
Study NCT03907475 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Biospecimen Collection
Description: Undergo blood sample collection
Study NCT03907475 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Biospecimen Collection
Description: Undergo blood sample collection
Study NCT03907475 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Capecitabine
Description: Given PO
Study NCT03907475 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Carboplatin
Description: Given IV
Study NCT03907475 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Computed Tomography
Description: Undergo CT
Study NCT03907475 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Computed Tomography
Description: Undergo CT
Study NCT03907475 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Durvalumab
Description: Given IV
Study NCT03907475 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Durvalumab
Description: Given IV
Study NCT00813072 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PEP02
Description: 120 mg/m2, IV infusion for 90 minutes on day 1 of each 21 day as a treatment cycle.~Number of Cycles: until progression or unacceptable toxicity develops.
Study NCT00813072 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: irinotecan
Description: 300 mg/m2, IV infusion on day 1 of each 21 day as a treatment cycle. Number of Cycles: until progression or unacceptable toxicity develops.
Study NCT00813072 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: docetaxel
Description: 75 mg/m2, IV infusion for 60 minutes on day 1 of each 21 day as a treatment cycle.~Number of Cycles: until progression or unacceptable toxicity develops.
Study NCT00529087 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: N-methylnaltrexone bromide (MOA-728)
Description: Subcutaneous
Study NCT00529087 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: placebo
Study NCT00323453 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Open appendectomy using Alexis Wound Retractor followed by standardized wound closure
Description: The control arm subjects will undergo open appendectomy and standardized wound closure. The experimental arm will undergo open appendectomy utilizing the Alexis® retractor, followed by standardized wound closure.
Study NCT00323453 — intervention group
Intervention type: PROCEDURE
Group type: PLACEBO_COMPARATOR
Intervention: Open appendectomy with standardized wound closure
Description: The control arm subjects will undergo open appendectomy and standardized wound closure. The experimental arm will undergo open appendectomy utilizing the Alexis® retractor, followed by standardized wound closure.
Study NCT03956563 — intervention group
Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Youlaser MT Group 2
Description: Youlaser MT is a laser device including two laser sources emitting at 10600 nm (CO2) and 1540 nm (Ga-As) intended to be used for gynaecological applications.~Each patient in the control arm will receive 3 simulated laser treatments every 30 days.~A placebo consists in a sham device laser that simulates the acoustic signal even if it does not deliver any laser radiation to the subject.
Study NCT01191450 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Chlorthalidone 25 mg + amiloride hydrochloride 5 mg
Description: Chlorthalidone 25 mg + amiloride hydrochloride 5 mg - one oral tablet a day in the morning during approximately 12 weeks
Study NCT01191450 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Higroton® Laboratório Novartis
Description: Chlortalidone 25mg - oral tablet a day in the morning during approximately 12 weeks
Study NCT04117477 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Xylitol
Description: Xylitol dental wipes
Study NCT04117477 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo dental wipes
Study NCT01034683 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: lobaplatin , 5-FU ,leucovorin
Description: Participants received 2-hour lobaplatin (30 mg/m2 on day 1) and a 2-hour infusion of leucovorin (LV; 200 mg/m2 on days 1-5) followed by a 4-hour infusion of 5-FU (650 mg/m2 on days 1-5). Treatment was repeated every 21 days.
Study NCT01513447 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Intracutaneous injections
Description: Four intracutaneous injections: two sites lateral to the lumbosacral spine and two sites 2-3 centimeters below and 1- 2 centimeters medial to the original two injections sites. 0.1 millimeters of the study drug is injected between the dermal layers at each of the four sites. The injections are administered sequentially, with the series of four injections, performed two at a time, completed in 20-30 seconds.
Study NCT01513447 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Intracutaneous injections
Description: Four intracutaneous injections: two sites lateral to the lumbosacral spine and two sites 2-3 centimeters below and 1- 2 centimeters medial to the original two injections sites. 0.1 millimeters of the study drug is injected between the dermal layers at each of the four sites. The injections are administered sequentially, with the series of four injections, performed two at a time, completed in 20-30 seconds.
Study NCT00093743 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: fludarabine phosphate
Description: Given IV
Study NCT00093743 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: cyclosporine
Description: Given IV or PO
Study NCT00093743 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: total-body irradiation
Description: Undergo TBI
Study NCT00093743 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: allogeneic bone marrow transplantation
Description: Undergo allogeneic bone marrow transplantation
Study NCT00093743 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: allogeneic hematopoietic stem cell transplantation
Description: Undergo allogeneic PBSC transplantation
Study NCT00093743 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: peripheral blood stem cell transplantation
Description: Undergo allogeneic PBSC transplantation
Study NCT00093743 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: mycophenolate mofetil
Description: Given PO or IV
Study NCT00212862 — intervention group
Intervention type: OTHER
Intervention: Patients with chemotherapy induced anemia
Description: Physicians are instructed to continue to treat all patients according to their own best clinical judgment, but to submit information on the parameters and outcomes of this treatment to the database. Patients will have to fill the questionaire at the time of enrollment and baseline.
Study NCT01298219 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lubiprostone
Description: 24 mcg administered orally twice daily (BID)
Study NCT03956563 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Youlaser MT Group 1
Description: Youlaser MT is a laser device including two laser sources emitting at 10600 nm (CO2) and 1540 nm (Ga-As) intended to be used for gynaecological applications.~Each patient in the active arm will receive 3 laser treatments with the laser: one treatment administration every 30 days.